Post by SOTIO Biotech

July is #SarcomaAwarenessMonth, dedicated to recognizing the impact of these rare and complex cancers. At SOTIO, we’re rapidly advancing our investigational antibody-drug conjugate SOT106 with plans to enter the clinic later this year. SOT106 recently received Orphan Drug Designation (#ODD) from the U.S. FDA, underscoring both the urgent need for new sarcoma therapies and the potential of this program. #ADC #SarcomaInnovation #RareCancer #RareDisease #OncologyInnovation #jsmePPF

Video Content